Oncopeptides
Jarl Ulf Jungnelius is the Chief Medical Officer at TME Pharma since February 2017 and a Managing Partner at HealthCom GmbH since May 2014, focusing on oncology clinical research and regulatory strategy. Additionally, Jungnelius has served on the Board of Directors for several organizations, including Biovica International AB, Oncopeptides AB, Ryvu Therapeutics, and Isofol Medical AB, where the role included CEO and Chairman of the Board. Jungnelius was also a member of the Supervisory Board for Beactica Therapeutics and CarpoNovum AB. Education includes a Doctor of Medicine (MD) degree from Karolinska Institutet, completed between 1975 and 1990.
This person is not in any teams
This person is not in any offices
Oncopeptides
2 followers
Oncopeptides is a clinical development pharmaceutical company focused on bringing anti-cancer research as treatments for the benefit of patients.